LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 84

Search options

  1. Article ; Online: Thiotepa, Busulfan, Cyclophosphamide

    Lebon Delphine / Debureaux Pierre-Edouard / Royer Bruno / Gruson Bérengère / Joris Magalie / Votte Patrick / Marolleau Jean-Pierre / Morel Pierre

    Medical Sciences, Vol 11, Iss 14, p

    Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma

    2023  Volume 14

    Abstract: In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen. ... ...

    Abstract In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen. However, 11 percent of the patients died due to toxicity. Besides conventional survival, progression-free survival and treatment related mortality analyses, a competing-risk analysis was applied to our cohort of twenty-four consecutive patients with primary or secondary central nervous system lymphoma who underwent autologous stem cell transplantation after thiotepa busulfan cyclophosphamide conditioning. The two-year overall survival and progression-free survival rates were 78 percent and 65 percent, respectively. The treatment-related mortality rate was 21 percent. The competing risks analysis demonstrate that age 60 or over and the infusion of less than 4.6 × 106/kg CD34+ stem cells were significant adverse prognostic factors for overall survival. Autologous stem cell transplantation with thiotepa busulfan cyclophosphamide conditioning was associated with sustained remission and survival. Nevertheless, the intensive thiotepa busulfan cyclophosphamide conditioning regimen was highly toxic, especially in older patients. Thus, our results suggest that future studies should aim at identifying the subgroup of patients who will really benefit of the procedure and/or to reduce the toxicity of future conditioning regimen.
    Keywords autologous hematopoietic stem cell transplantation ; central nervous system lymphoma ; infections ; conditioning ; adverse events ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma.

    Ascione, Sophia / Harel, Stéphanie / Besson, Florent L / Belkhir, Rakiba / Henry, Julien / Royer, Bruno / Arnulf, Bertrand / Mariette, Xavier / Seror, Raphaèle

    Haematologica

    2023  Volume 108, Issue 11, Page(s) 3160–3164

    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Plasmacytoma/drug therapy ; Bone Neoplasms/drug therapy ; Bone Neoplasms/prevention & control
    Language English
    Publishing date 2023-11-01
    Publishing country Italy
    Document type Letter
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.282214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Traitement du myélome multiple.

    Talbot, Alexis / Royer, Bruno / Roussel, Murielle

    La Revue du praticien

    2019  Volume 68, Issue 7, Page(s) 787–791

    Abstract: Multiple myeloma treatment. Multiple myeloma is still an incurable disease but the recent therapeutics progress have revolutionized its management and improved prognosis. The first-line treatment of younger patients undoubtedly rests on the therapeutic ... ...

    Title translation Multiple myeloma treatment.
    Abstract Multiple myeloma treatment. Multiple myeloma is still an incurable disease but the recent therapeutics progress have revolutionized its management and improved prognosis. The first-line treatment of younger patients undoubtedly rests on the therapeutic intensification with autologous peripheral stem cell transplantation. The induction and especially the consolidation phases are complementary in this intensive program with the aim to obtain a deep and lasting response. Triple associations with proteasome inhibitor, immunomodulator and dexamethasone are the standard treatment. Maintenance by Lenalidomide will certainly become a standard of care in the near future for a period yet to be defined. For older patients the associations VMP and Rd are validated and are to be discussed on a case-by-case basis. In relapse, the combinations of chemotherapy are also the rule.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib ; Humans ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local ; Thalidomide ; Transplantation, Autologous
    Chemical Substances Thalidomide (4Z8R6ORS6L) ; Bortezomib (69G8BD63PP)
    Language French
    Publishing date 2019-04-03
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.

    Nicol, Martin / Vergaro, Giuseppe / Damy, Thibaud / Kharoubi, Mounira / Baudet, Mathilde / Canuti, Elena Sofia / Aimo, Alberto / Castiglione, Vincenzo / Emdin, Michele / Royer, Bruno / Harel, Stephanie / Cohen-Solal, Alain / Arnulf, Bertrand / Logeart, Damien

    Frontiers in cardiovascular medicine

    2023  Volume 10, Page(s) 1179968

    Abstract: Background: Both light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis are types of cardiac amyloidosis (CA) that require accurate prognostic stratification to plan therapeutic strategies and follow-ups. Cardiac biomarkers, e.g., N-terminal ... ...

    Abstract Background: Both light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis are types of cardiac amyloidosis (CA) that require accurate prognostic stratification to plan therapeutic strategies and follow-ups. Cardiac biomarkers, e.g., N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (Hs-cTnT), remain the cornerstone of the prognostic assessment. An increased level of soluble suppression of tumorigenesis-2 (sST2) is predictive of adverse events [all-cause death and heart failure (HF) hospitalizations] in patients with HF. This study aimed to evaluate the prognostic value of circulating sST2 levels in AL-CA and ATTR-CA.
    Methods: We carried out a multicenter study including 133 patients with AL-CA and 152 patients with ATTR-CA. During an elective outpatient visit for the diagnosis of CA, Mayo Clinic staging [NT-proBNP, Hs-cTnT, differential of free light chains (DFLCs)] and sST2 were assessed for all AL patients. Gillmore staging [including estimated glomerular filtration rate (eGFR), NT-proBNP] and Grogan staging (including NT-proBNP and Hs-cTnT) were assessed for TTR-CA patients.
    Results: The median age was 73 years [interquartile range (IQR) 61-81], and 53% were men. The endpoint was the composite of all-cause death or first HF-related hospitalization. The median follow-up was 20 months (IQR 3-34) in AL amyloidosis and 33 months (6-45) in TTR amyloidosis. The primary outcome occurred in 70 (53%) and 99 (65%) of AL and TTR patients, respectively. sST2 levels were higher in patients with AL-CA than in patients with ATTR-CA: 39 ng/L (26-80) vs. 32 ng/L (21-46),
    Conclusion: sST2 level is a relevant predictor of death and HF hospitalization in AL cardiac amyloidosis and adds prognostic stratification on top of NT-proBNP, Hs cTnT, and DFLC.
    Language English
    Publishing date 2023-08-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2781496-8
    ISSN 2297-055X
    ISSN 2297-055X
    DOI 10.3389/fcvm.2023.1179968
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Thiotepa intrathecal injections for myelomatous central nervous system involvement.

    Claudel, Alexis / Talbot, Alexis / Harel, Stéphanie / Royer, Bruno / Naelle, Lombion / Zagdanski, Anne-Marie / Madelaine, Isabelle / Lemaire, Pierre / Arnulf, Bertrand

    British journal of haematology

    2021  Volume 193, Issue 2, Page(s) e9–e12

    MeSH term(s) Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Central Nervous System/drug effects ; Central Nervous System/pathology ; Female ; Humans ; Incidence ; Injections, Spinal ; Male ; Meningeal Neoplasms/drug therapy ; Meningeal Neoplasms/pathology ; Methylprednisolone/administration & dosage ; Methylprednisolone/therapeutic use ; Middle Aged ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Multiple Myeloma/epidemiology ; Neuroprotective Agents/administration & dosage ; Neuroprotective Agents/therapeutic use ; Plasmacytoma/cerebrospinal fluid ; Plasmacytoma/diagnosis ; Plasmacytoma/drug therapy ; Safety ; Thiotepa/administration & dosage ; Thiotepa/therapeutic use ; Treatment Outcome
    Chemical Substances Antineoplastic Agents, Alkylating ; Neuroprotective Agents ; Thiotepa (905Z5W3GKH) ; Methylprednisolone (X4W7ZR7023)
    Language English
    Publishing date 2021-03-09
    Publishing country England
    Document type Letter
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17343
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.

    Debureaux, Pierre-Edouard / Forgeard, Nathalie / Elessa, Dikelele / Harel, Stéphanie / Frenzel, Laurent / Royer, Bruno / Talbot, Alexis / Choquet, Sylvain / Davi, Frederic / Nguyen-Khac, Florence / Cuccuini, Wendy / Cheminant, Morgane / Bravetti, Clotilde / Lazarian, Gregory / Kaltenbach, Sophie / Hermine, Olivier / Roos-Weil, Damien / Espéli, Marion / Balabanian, Karl /
    Arnulf, Bertrand

    Haematologica

    2024  Volume 109, Issue 1, Page(s) 325–330

    MeSH term(s) Humans ; Waldenstrom Macroglobulinemia/drug therapy ; Tyrosine Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase ; Inflammation ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Tyrosine Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; Protein Kinase Inhibitors
    Language English
    Publishing date 2024-01-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2023.283141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.

    Forgeard, Nathalie / Elessa, Dikélélé / Carpinteiro, Alexander / Belhadj, Karim / Minnema, Monique / Roussel, Murielle / Huart, Antoine / Javaugue, Vincent / Pascal, Laurent / Royer, Bruno / Talbot, Alexis / Gounot, Romain / Hegenbart, Ute / Schonland, Stefan / Karlin, Lionel / Harel, Stéphanie / Kastritis, Efstathios / Bridoux, Frank / Jaccard, Arnaud /
    Arnulf, Bertrand

    Blood

    2023  Volume 143, Issue 8, Page(s) 734–737

    MeSH term(s) Humans ; Immunoglobulin Light-chain Amyloidosis/drug therapy ; Retrospective Studies ; Amyloidosis/drug therapy ; Antineoplastic Agents/therapeutic use ; Immunoglobulin Light Chains
    Chemical Substances Antineoplastic Agents ; Immunoglobulin Light Chains
    Language English
    Publishing date 2023-12-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023022937
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Multiple myeloma occurring in a case of Niemann-Pick disease Type B: A pathophysiological link?

    Portier, Elodie / Talbot, Alexis / Nguyen, Yann / Royer, Bruno / Pettazzoni, Magali / Ben Salah, Imen / Trichet, Catherine / Vercellino, Laetitia / Arnulf, Bertrand / Belmatoug, Nadia

    British journal of haematology

    2022  Volume 197, Issue 4, Page(s) e53–e55

    MeSH term(s) Humans ; Multiple Myeloma/complications ; Multiple Myeloma/diagnosis ; Mutation ; Niemann-Pick Disease, Type B/complications ; Niemann-Pick Disease, Type B/diagnosis ; Niemann-Pick Diseases
    Language English
    Publishing date 2022-02-10
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18050
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.

    Abecassis, Audrey / Roders, Nathalie / Fayon, Maxime / Choisy, Caroline / Nelson, Elisabeth / Harel, Stephanie / Royer, Bruno / Villesuzanne, Camille / Talbot, Alexis / Garrick, David / Goodhardt, Michele / Fermand, Jean-Paul / Burbridge, Mike / Arnulf, Bertrand / Bories, Jean-Christophe

    EJHaem

    2022  Volume 3, Issue 3, Page(s) 970–974

    Abstract: Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at ... ...

    Abstract Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at different stages of the disease and investigated their phenotype and capacity to generate functional CAR-T directed against CS1 or B Cell Maturation antigen. We found a decrease in naive T cells and elevated frequencies of exhaustion markers in T cells from treated MM patients. Interestingly, individuals treated with daratumumab display elevated ratios of central memory T cells. CAR-T derived from patients at relapse show reduced in vitro expansion and cytotoxic capacities in response to MM cells compared to those produced at diagnosis. Of note, CAR-T from daratumumab treated patients display intermediate defects. Reduced anti-myeloma activity of CAR T cells from treated patients was also observed in a mouse model. Our findings suggest that T cell defects in MM patients, specifically during relapse, have a major impact on their capacity to generate efficient therapeutic CAR-T. Selecting naive or central memory T cell subsets to generate therapeutic T cells could improve the CAR-T therapy for MM.
    Language English
    Publishing date 2022-06-21
    Publishing country United States
    Document type Journal Article
    ISSN 2688-6146
    ISSN (online) 2688-6146
    DOI 10.1002/jha2.479
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients.

    Elessa, Dikelele / Debureaux, Pierre-Edouard / Villesuzanne, Camille / Davi, Frederic / Bravetti, Clotilde / Harel, Stephanie / Talbot, Alexis / Oksenhendler, Eric / Malphettes, Marion / Thieblemont, Catherine / Moatti, Hannah / Maarek, Odile / Arnulf, Bertrand / Royer, Bruno

    British journal of haematology

    2022  Volume 197, Issue 6, Page(s) 728–735

    Abstract: Waldenström's macroglobulinaemia (WM) is a B-cell neoplasm resulting from bone marrow lymphoplasmacytic infiltration and monoclonal IgM secretion. Some patients present concomitant inflammatory syndrome attributed to the disease activity; we named this ... ...

    Abstract Waldenström's macroglobulinaemia (WM) is a B-cell neoplasm resulting from bone marrow lymphoplasmacytic infiltration and monoclonal IgM secretion. Some patients present concomitant inflammatory syndrome attributed to the disease activity; we named this syndrome inflammatory WM (IWM). We retrospectively analysed all WM patients seen in a single tertiary referral centre from January 2007 to May 2021, and after excluding aetiologies for the inflammatory syndrome using a pertinent blood workup, including C-reactive protein (CRP), and imaging, we identified 67 (28%) IWM, 166 (68%) non-IWM, and nine (4%) WM with inflammatory syndrome of unknown origin. At treatment initiation, IWM patients had more severe anaemia (median Hb 90 vs 99 g/l; p < 0.01), higher platelet count (median 245 vs 196 × 109/l; p < 0.01) and comparable serum IgM level (median 24.9 vs 23.0 g/l; p = 0.28). A positive correlation was found between inflammatory and haematological responses (minimal response or better) (odds ratio 32.08; 95% confidence interval 8.80-98.03; p < 0.001). Overall survivals (OS) were similar (median OS: 17 vs 20 years; p = 0.11) but time to next treatment (TNT) was significantly shorter for IWM (TNT1: 1.6 vs 4.8 years, p < 0.0001). IWM mostly shared the same presentation and outcome as WM without inflammatory syndrome.
    MeSH term(s) Humans ; Immunoglobulin M ; Retrospective Studies ; Waldenstrom Macroglobulinemia
    Chemical Substances Immunoglobulin M
    Language English
    Publishing date 2022-04-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18157
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top